The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Successful treatment of first-episode psychosis is one of the major factors that impacts long-term prognosis. Currently, there are no satisfactory biological markers (biomarkers) to predict which patients with a first-episode psychosis will respond to which treatment. In addition, a non-negligible rate of patients does not respond to any treatment or may develop side effects that affect adherence to the treatments as well as negatively impact physical health. Thus, there clearly is a pressing need for defining biomarkers that may be helpful to predict response to treatment and sensitivity to side effects in first-episode psychosis. The present systematic review provides (1) trials that assessed biological markers associated with antipsychotic response or side effects in first-episode psychosis and (2) potential biomarkers associated with biological disturbances that may guide the choice of conventional treatments or the prescription of innovative treatments. Trials including first-episode psychoses are few in number. Most of the available data focused on pharmacogenetics markers with so far only preliminary results. To date, these studies yielded-beside markers for metabolism of antipsychotics-no or only a few biomarkers for response or side effects, none of which have been implemented in daily clinical practice. Other biomarkers exploring immunoinflammatory, oxidative, and hormonal disturbances emerged as biomarkers of first-episode psychoses in the last decades, and some of them have been associated with treatment response. In addition to pharmacogenetics, further efforts should focus on the association of emergent biomarkers with conventional treatments or with innovative therapies efficacy, where some preliminary data suggest promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Self-citationCommon variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677
Self-citationNeuroendocrine perspectives on social attachment and love
Sue Carter, C. (1998) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(98)00055-9 · Cited by 1,425
Kapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980
Self-citationAmminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501
Kimonides, V. G., Khatibi, N. H., Svendsen, C. N., Sofroniew, M. V., & Herbert, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1852 · Cited by 438
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment
Drancourt, N., Etain, B., Lajnef, M., Henry, C., Raust, A., Cochet, B., Mathieu, F., Gard, S., MBailara, K., Zanouy, L., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01917.x · Cited by 292
Self-citationMondelli, V., Dazzan, P., Hepgul, N., Di Forti, M., Aas, M., D'Albenzio, A., Di Nicola, M., Fisher, H., Handley, R., Marques, T. R., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.013 · Cited by 278
Duffy, D., Rouilly, V., Libri, V., Hasan, M., Beitz, B., David, M., Urrutia, A., Bisiaux, A., LaBrie, S. T., Dubois, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.002 · Cited by 242
Ryan, M. C. M., Sharifi, N., Condren, R., & Thakore, J. H. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2003.08.011 · Cited by 225
Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis
Tourjman, V., Kouassi, É., Koué, M.-È., Rocchetti, M., Fortin-Fournier, S., Fusar-Poli, P., & Potvin, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.011 · Cited by 224
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Self-citationSerum and gene expression profile of cytokines in first-episode psychosis
Di Nicola, M., Cattaneo, A., Hepgul, N., Di Forti, M., Aitchison, K. J., Janiri, L., Murray, R. M., Dazzan, P., Pariante, C. M., & Mondelli, V. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.06.010 · Cited by 217
Oxytocin revisited: Its role in cardiovascular regulation
Gutkowska, J., & Jankowski, M. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02235.x · Cited by 208
Howes, O. D., & Kapur, S. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.138578 · Cited by 203
Self-citationMortality in Schizophrenia and Other Psychoses: A 10-Year Follow-up of the ӔSOP First-Episode Cohort
Reininghaus, U., Dutta, R., Dazzan, P., Doody, G. A., Fearon, P., Lappin, J., Heslin, M., Onyejiaka, A., Donoghue, K., Lomas, B., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu138 · Cited by 156
Mondelli, V., Pariante, C. M., Navari, S., Aas, M., D'Albenzio, A., Di Forti, M., Handley, R., Hepgul, N., Marques, T. R., Taylor, H., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.021 · Cited by 144
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders
Rubin, L. H., Carter, C. S., Bishop, J. R., Pournajafi-Nazarloo, H., Drogos, L. L., Hill, S. K., Ruocco, A. C., Keedy, S. K., Reilly, J. L., Keshavan, M. S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu027 · Cited by 127
Aas, M., Dazzan, P., Mondelli, V., Toulopoulou, T., Reichenberg, A., Di Forti, M., Fisher, H. L., Handley, R., Hepgul, N., Marques, T., et al. (2011) · Psychological Medicine · doi:10.1017/s0033291710001170 · Cited by 124
Innovative solutions to novel drug development in mental health
Insel, T. R., Voon, V., Nye, J. S., Brown, V. J., Altevogt, B. M., Bullmore, E. T., Goodwin, G. M., Howard, R. J., Kupfer, D. J., Malloch, G., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.022 · Cited by 124
Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.004 · Cited by 102
Strous, R. D., Maayan, R., Lapidus, R., Goredetsky, L., Zeldich, E., Kotler, M., & Weizman, A. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.005 · Cited by 92
Functional magnetic resonance imaging and the neurobiology of vasopressin and oxytocin
FERRIS, C. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00425-1 · Cited by 75
Cullen, A. E., Zunszain, P. A., Dickson, H., Roberts, R. E., Fisher, H. L., Pariante, C. M., & Laurens, K. R. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.010 · Cited by 75
Impaired Metabolic Reactivity to Oxidative Stress in Early Psychosis Patients
Fournier, M., Ferrari, C., Baumann, P. S., Polari, A., Monin, A., Bellier-Teichmann, T., Wulff, J., Pappan, K. L., Cuenod, M., Conus, P., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu053 · Cited by 48
Cited by
Özdin, S., & Böke, Ö. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.11.043 · Cited by 129
Prata, J., Santos, S. G., Almeida, M. I., Coelho, R., & Barbosa, M. A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0938-y · Cited by 115
Assessing and Improving the Quality in Mental Health Services
Samartzis, L., & Talias, M. A. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010249 · Cited by 92
“The difficulty is compounded by the lack of reliable biological markers in psychiatric evaluation, which makes it difficult to quantify any improvement after hospitalization, or in general after hospital or out-of-hospital pharmacotherapy and psychotherapy interventions [42].”
BackgroundKose, M., Pariante, C. M., Dazzan, P., & Mondelli, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.612471 · Cited by 61
Llorca-Bofí, V., Bioque, M., Font, M., Gich, I., & Mur, M. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.07.023 · Cited by 12
Metadata
- Authors
- Fond, G., d'Albis, M.-A., Jamain, S., Tamouza, R., Arango, C., Fleischhacker, W. W., Glenthoj, B., Leweke, M., Lewis, S., McGuire, P., Meyer-Lindenberg, A., Sommer, I. E., Winter-van Rossum, I., Kapur, S., Kahn, R. S., Rujescu, D., & Leboyer, M.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-10
- Volume
- 41
- Issue
- 3
- Pages
- 559-573
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2095675080
- Cited by
- 96
- References
- 29
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.